Venous thromboembolism in the elderly

Summary

While the magnitude of venous thromboembolism (VTE) increases dramatically with advancing age,relatively little is known about the contemporary management of VTE in the elderly and the impact of age on associated short- and long-term outcomes. The objectives of this population-based study were to compare the clinical characteristics,treatment practices,and outcomes of subjects ≥65 years with VTE to those of younger patients.The medical records of residents of the Worcester (MA, USA) metropolitan area with ICD-9 codes consistent with VTE during 1999, 2001, and 2003 were independently validated and reviewed by trained data abstractors. Information about patients’ demographic and clinical characteristics, hospital management practices, and hospital and long-term outcomes was collected. There were a total of 1,897 validated events of VTE – 1,048 (55%) occurred in patients ≥65 years of age. Patients ≥65 years were less likely to have “unprovoked” VTE than younger patients.They were less likely to receive parenteral anticoagulation or warfarin as acute treatment. Rates of recurrent VTE did not differ significantly between patients 65 years of age or older compared to younger patients but the adjusted rates of major bleeding were increased approximately two-fold in older patients. In conclusion, advancing age is not a predictor of recurrent VTE but is associated with a significant increase in major bleeding episodes. Physicians treating elderly patients with VTE should continue to base their decisions on clinical characteristics previously shown to impact the risk of recurrent VTE. These decisions must be tempered by our observation that major bleeding occurs frequently in these patients.

Keywords

Aging - bleeding - elderly - venous thromboembolism

• References

• 1 Spencer FA, Emery C, Lessard D. et al. The Worcester Venous Thromboembolism study. A population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 2006; 21: 722-727.
• 2 Silverstein MD, Heit JA, Mohr DN. et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism. A 25-year population-based study. Arch Intern Med 1998; 158: 585-593.
• 3 Anderson Jr FA, Wheeler HB, Goldberg RJ. et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. Arch Intern Med 1991; 151: 933-938.
• 4 Heit JA, Silverstein MD, Mohr DN. et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001; 86: 452-463.
• 5 Heit JA, Mohr DN, Silverstein MD. et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism. A population-based cohort study. Arch Intern Med 2000; 160: 761-768.
• 6 White RH, Zhou H, Romano PS. Length of hospital stay for treatment of deep venous thrombosis and the incidence of recurrent thromboembolism. Arch Intern Med 1998; 158: 1005-1010.
• 7 Prandoni P, Lensing AW, Cogo A. et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
• 8 Fiessinger JN, Huisman MV, Davidson BL. et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis. A randomized trial. J Am Med Assoc 2005; 293: 681-689.
• 9 Buller HR, Davidson BL, Decousus H. et al. for the Matisse Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep vein thrombosis. A randomized trial. Ann Intern Med 2004; 140: 867-873.
• 10 Kearon C, Ginsberg JS, Kovacs MJ. et al. Comparison of low-intensity warfarin therapy with conventional intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349: 631-639.
• 11 Lopez-Jiminez L, Montero M, Gonzalez-Fajardo JA. et al. Venous thromboembolism in very elderly patients: findings from a prospective registry (RIETE). Haematologica 2006; 91: 1046-1051.
• 12 Jick H, Slone D, Borda IT. et al. Efficacy and toxicity of heparin in relation to age and sex. N Engl J Med 1968; 279: 284-286.
• 13 Basu D, Gallus AS, Hirsh J. et al. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972; 287: 324-327.
• 14 Campbell NR, Hull R, Brant R. et al. Aging and heparin-related bleeding. Arch Intern Med 1996; 156: 857-860.
• 15 Cromheecke ME, Levi M, Colly LP. et al. Oral anti-coagulation self-management and management by a specialist anticoagulation clinic: a randomized crossover comparison. Lancet 2000; 356: 97-102.
• 16 Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients wiht atrial fibrillation. Arch Intern Med. 1996 156. 409-416.
• 17 European Atrial Fibrillation Trial (EAFT) Study Group. Optimal oral anticoagulant therapy in patients with non-rheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med. 1995 333. 5-10.
• 18 Kuijer PM, Hutten BA, Prins MH. et al. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999; 159: 457-460.
• 19 Pengo V, Legnani C, Noventa F. et al. on behalf of the ISCOAT Study Group Oral anticoagulant therapy in patients wiht nonrheumatic atrial fibrillation and risk of bleeding: a multicenter inception cohort study. Thromb Haemost 2001; 85: 418-422.
• 20 Hirsh J, O’Donnell M, Eikelboom JW. Beyond unfractionated heparin and warfarin: current and future advances. Circulation 2007; 116: 552-560.